Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
The ethical questions surrounding the recruitment of patients for clinical trials become more complicated when the recruiting physicians receive financial benefits for each patient enrolled.
Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?”
An ethical case describes the use of a pharmacy's database to market directly to their patients without either patient consent or disclosure of the marketing intent of the materials they received.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.